ES2947685T3 - Aplicación del nuevo inhibidor de la tirosinacinasa, anlotinib, en osteosarcoma y condrosarcoma - Google Patents
Aplicación del nuevo inhibidor de la tirosinacinasa, anlotinib, en osteosarcoma y condrosarcoma Download PDFInfo
- Publication number
- ES2947685T3 ES2947685T3 ES19740851T ES19740851T ES2947685T3 ES 2947685 T3 ES2947685 T3 ES 2947685T3 ES 19740851 T ES19740851 T ES 19740851T ES 19740851 T ES19740851 T ES 19740851T ES 2947685 T3 ES2947685 T3 ES 2947685T3
- Authority
- ES
- Spain
- Prior art keywords
- osteosarcoma
- anlotinib
- pharmaceutically acceptable
- chondrosarcoma
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810058487.7A CN107970241B (zh) | 2018-01-22 | 2018-01-22 | 一种新型酪氨酸激酶抑制剂安罗替尼在制备抑制骨肉瘤的药物中的应用 |
| PCT/CN2019/071846 WO2019141170A1 (zh) | 2018-01-22 | 2019-01-16 | 一种新型酪氨酸激酶抑制剂-安罗替尼在骨肉瘤和软骨肉瘤的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2947685T3 true ES2947685T3 (es) | 2023-08-16 |
Family
ID=62006233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES19740851T Active ES2947685T3 (es) | 2018-01-22 | 2019-01-16 | Aplicación del nuevo inhibidor de la tirosinacinasa, anlotinib, en osteosarcoma y condrosarcoma |
Country Status (6)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107970241B (zh) * | 2018-01-22 | 2020-05-22 | 正大天晴药业集团股份有限公司 | 一种新型酪氨酸激酶抑制剂安罗替尼在制备抑制骨肉瘤的药物中的应用 |
| US11419862B2 (en) | 2018-03-14 | 2022-08-23 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Quinoline derivative for treatment of nasopharyngeal carcinoma |
| WO2020187152A1 (zh) * | 2019-03-15 | 2020-09-24 | 正大天晴药业集团股份有限公司 | 治疗小细胞肺癌的联用药物组合物 |
| CN111821459A (zh) * | 2019-04-17 | 2020-10-27 | 正大天晴药业集团股份有限公司 | 用于联合治疗骨肉瘤的喹啉类化合物 |
| CN111821302A (zh) * | 2019-04-18 | 2020-10-27 | 正大天晴药业集团股份有限公司 | 用于联合治疗软骨肉瘤的喹啉类化合物 |
| AU2020259565A1 (en) * | 2019-04-19 | 2021-12-02 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Quinoline compound or pharmaceutically acceptable salt thereof for treating Ewing's sarcoma |
| JP2022532189A (ja) * | 2019-05-10 | 2022-07-13 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | 軟部肉腫の併用療法用キノリン誘導体 |
| EP3973963A4 (en) * | 2019-05-23 | 2023-06-14 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | QUINOLINE DERIVATIVES FOR THE TREATMENT OF HEAD AND NECK CANCER |
| CN114761010B (zh) * | 2019-11-25 | 2024-04-16 | 正大天晴药业集团股份有限公司 | 喹唑啉衍生物或其盐的联用药物组合物及其用途 |
| CN112043698B (zh) * | 2020-08-03 | 2023-04-25 | 吴宏伟 | 一组小分子药物在制备抑制肉瘤药物中的应用 |
| CN113456797B (zh) * | 2021-06-18 | 2024-03-08 | 暨南大学 | 长春碱类衍生物在制备治疗骨肉瘤和/或软组织肉瘤药物中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8148532B2 (en) | 2007-03-14 | 2012-04-03 | Guoqing Paul Chen | Spiro substituted compounds as angiogenesis inhibitors |
| CN105311030B (zh) | 2014-06-06 | 2020-03-24 | 正大天晴药业集团股份有限公司 | 用于抗肿瘤的螺取代化合物 |
| CN105311029A (zh) | 2014-06-06 | 2016-02-10 | 正大天晴药业集团股份有限公司 | 抗肿瘤活性的喹啉衍生物 |
| US9751859B2 (en) | 2015-05-04 | 2017-09-05 | Advenchen Pharmaceuticals, LLC | Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and its salts |
| EP3120851A1 (en) * | 2015-07-21 | 2017-01-25 | Pangaea Biotech S.L. | 4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers |
| US10709708B2 (en) * | 2016-03-17 | 2020-07-14 | The University Of North Carolina At Chapel Hill | Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor |
| CN107970241B (zh) * | 2018-01-22 | 2020-05-22 | 正大天晴药业集团股份有限公司 | 一种新型酪氨酸激酶抑制剂安罗替尼在制备抑制骨肉瘤的药物中的应用 |
-
2018
- 2018-01-22 CN CN201810058487.7A patent/CN107970241B/zh active Active
- 2018-09-20 WO PCT/CN2018/106625 patent/WO2019140937A1/zh active Application Filing
-
2019
- 2019-01-16 ES ES19740851T patent/ES2947685T3/es active Active
- 2019-01-16 JP JP2020540394A patent/JP7324759B2/ja active Active
- 2019-01-16 KR KR1020207024248A patent/KR20200111752A/ko not_active Application Discontinuation
- 2019-01-16 EP EP19740851.1A patent/EP3744325B1/en active Active
- 2019-01-16 CN CN201980008849.4A patent/CN111683661B/zh active Active
- 2019-01-16 WO PCT/CN2019/071846 patent/WO2019141170A1/zh active Application Filing
- 2019-01-16 CN CN202210965476.3A patent/CN115337304A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN111683661B (zh) | 2022-07-26 |
| EP3744325A1 (en) | 2020-12-02 |
| EP3744325B1 (en) | 2023-06-07 |
| CN107970241A (zh) | 2018-05-01 |
| EP3744325A4 (en) | 2021-10-20 |
| CN115337304A (zh) | 2022-11-15 |
| JP7324759B2 (ja) | 2023-08-10 |
| JP2021510725A (ja) | 2021-04-30 |
| CN107970241B (zh) | 2020-05-22 |
| CN111683661A (zh) | 2020-09-18 |
| RU2020124923A (ru) | 2022-02-24 |
| WO2019141170A1 (zh) | 2019-07-25 |
| RU2020124923A3 (US20070167479A1-20070719-C00034.png) | 2022-04-26 |
| KR20200111752A (ko) | 2020-09-29 |
| WO2019140937A1 (zh) | 2019-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2947685T3 (es) | Aplicación del nuevo inhibidor de la tirosinacinasa, anlotinib, en osteosarcoma y condrosarcoma | |
| US10183017B2 (en) | Methods and uses of quinoline derivatives in the treatment of soft tissue sarcomas and pharmaceutical compositions for treatment of same | |
| US20200316053A1 (en) | Application of novel tyrosine kinase inhibitor, anlotinib, in osteosarcoma and chondrosarcoma | |
| PL231418B1 (pl) | 40-O-( 2-hydroksyetylo)- rapamycyna do zastosowania w leczeniu guzów litych płuc, innych niż nowotwór tkanki limfatycznej | |
| CN111012785B (zh) | 喹啉衍生物用于治疗甲状腺癌的方法和用途 | |
| CN109069500B (zh) | 一种用于治疗胃癌的喹啉衍生物 | |
| CN112057452A (zh) | 治疗非小细胞肺癌的喹啉衍生物 | |
| CN113710658A (zh) | 用于治疗尤因肉瘤的喹啉类化合物或其药学上可接受的盐 | |
| WO2023168036A1 (en) | Method of treatment including kras g12c inhibitors and shp2 inhibitors | |
| RU2787235C2 (ru) | Применение нового ингибитора тирозинкиназ, анлотиниба, при остеосаркоме и хондросаркоме | |
| Bacci et al. | Primary lymphoma of bone: long term results in patients treated with vincristine-adriamycin-cyclophosphamide and local radiation | |
| RU2392019C1 (ru) | Способ лечения местнораспространенного рака прямой кишки | |
| KR20200131265A (ko) | 비인두암을 치료하기 위한 퀴놀린 유도체 | |
| CN112294813A (zh) | 喹啉衍生物在治疗脊索瘤中的用途 | |
| WO2023144626A1 (en) | Pharmaceutical composition including phthalazinone derivative for co-administration with anticancer drug | |
| JP2019108385A (ja) | がん治療 | |
| CN111821459A (zh) | 用于联合治疗骨肉瘤的喹啉类化合物 | |
| CN111110681A (zh) | 喹啉衍生物联合卡培他滨在治疗肝癌的用途 | |
| Moreno Martin-Retortillo et al. | Synovial sarcoma in children. A single centre experience | |
| Carstens | Palliative radiation therapy in female genital cancers | |
| Samardzıskı et al. | Osteosarcoma: diagnosis and treatment |